Pediatrix Medical Group, Inc. $MD Holdings Raised by Squarepoint Ops LLC

Squarepoint Ops LLC lifted its position in shares of Pediatrix Medical Group, Inc. (NYSE:MD) by 234.6% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 81,142 shares of the company’s stock after acquiring an additional 56,889 shares during the period. Squarepoint Ops LLC owned about 0.09% of Pediatrix Medical Group worth $1,164,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in MD. Invesco Ltd. raised its holdings in shares of Pediatrix Medical Group by 9.3% during the first quarter. Invesco Ltd. now owns 863,269 shares of the company’s stock worth $12,509,000 after purchasing an additional 73,157 shares during the period. Nuveen LLC bought a new stake in shares of Pediatrix Medical Group during the 1st quarter valued at about $8,024,000. Russell Investments Group Ltd. grew its position in shares of Pediatrix Medical Group by 2.9% during the 1st quarter. Russell Investments Group Ltd. now owns 219,184 shares of the company’s stock valued at $3,176,000 after buying an additional 6,127 shares during the last quarter. Raymond James Financial Inc. raised its stake in Pediatrix Medical Group by 1.1% during the first quarter. Raymond James Financial Inc. now owns 236,323 shares of the company’s stock worth $3,424,000 after acquiring an additional 2,666 shares during the period. Finally, Hsbc Holdings PLC lifted its holdings in Pediatrix Medical Group by 64.3% in the first quarter. Hsbc Holdings PLC now owns 34,293 shares of the company’s stock worth $495,000 after acquiring an additional 13,417 shares during the last quarter. Institutional investors and hedge funds own 97.71% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. UBS Group upped their target price on Pediatrix Medical Group from $16.50 to $23.00 and gave the company a “neutral” rating in a report on Wednesday, November 5th. Truist Financial upped their price objective on Pediatrix Medical Group from $17.00 to $24.00 and gave the stock a “hold” rating in a research note on Monday, November 10th. Zacks Research upgraded Pediatrix Medical Group from a “hold” rating to a “strong-buy” rating in a research note on Friday, November 21st. Leerink Partners boosted their price target on shares of Pediatrix Medical Group from $14.50 to $17.00 and gave the company a “market perform” rating in a report on Friday, September 5th. Finally, Wall Street Zen raised shares of Pediatrix Medical Group from a “buy” rating to a “strong-buy” rating in a report on Saturday, October 4th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $21.00.

Insider Activity

In other Pediatrix Medical Group news, Director Laura A. Linynsky sold 10,000 shares of the company’s stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $21.65, for a total value of $216,500.00. Following the completion of the sale, the director directly owned 32,232 shares of the company’s stock, valued at approximately $697,822.80. This represents a 23.68% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Mark S. Ordan sold 23,000 shares of the firm’s stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $22.41, for a total transaction of $515,430.00. Following the transaction, the chief executive officer owned 302,805 shares of the company’s stock, valued at approximately $6,785,860.05. This trade represents a 7.06% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 43,478 shares of company stock worth $972,924. 0.90% of the stock is owned by company insiders.

Pediatrix Medical Group Stock Up 1.2%

MD stock opened at $21.90 on Friday. The firm’s 50-day moving average is $20.96 and its two-hundred day moving average is $17.04. The company has a market capitalization of $1.88 billion, a price-to-earnings ratio of 11.53 and a beta of 0.77. Pediatrix Medical Group, Inc. has a 52 week low of $11.84 and a 52 week high of $24.99. The company has a current ratio of 1.83, a quick ratio of 1.83 and a debt-to-equity ratio of 0.65.

Pediatrix Medical Group (NYSE:MD) last posted its quarterly earnings data on Monday, November 3rd. The company reported $0.67 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.21. Pediatrix Medical Group had a net margin of 8.44% and a return on equity of 20.45%. The business had revenue of $492.88 million for the quarter, compared to analyst estimates of $476.45 million. During the same quarter last year, the business earned $0.44 earnings per share. The business’s revenue for the quarter was down 3.6% on a year-over-year basis. On average, analysts forecast that Pediatrix Medical Group, Inc. will post 1.38 earnings per share for the current fiscal year.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.